Article - 24/10/2008 The game needs to be discovered Prof. Dr. Michael Reth is active in the field of immunology and signalling. He is an experienced scientist who is well aware of the difficulty and the cumbersome nature of deciphering signals and signalling pathways. The Freiburg bioss excellence cluster - the Centre of Biological Signalling Studies - is Reths brainchild. Karin Bundschuh from BioRegio Freiburg spoke with the scientist who works at the Max Planck Institute of Immunobiology and the…https://www.gesundheitsindustrie-bw.de/en/article/news/the-game-needs-to-be-discovered
Press release - 01/12/2020 Novel vaccine trial to activate T-cell responses against SARS-CoV-2 A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.https://www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
Press release - 12/10/2009 Immatics appoints Carsten Reinhardt as Chief Medical Officer The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer
Article - 28/06/2010 ATG:biosynthetics GmbH – Modular molecular systems of the future ATGbiosynthetics GmbH based in Merzhausen close to Freiburg produces biological systems that can combine gene constituents following a construction kit principle. The company provides the pharmaceutical industry and basic researchers with products that have specifically chosen properties.https://www.gesundheitsindustrie-bw.de/en/article/news/atg-biosynthetics-gmbh-modular-molecular-systems-of-the-future
Press release - 04/12/2009 Papillomavirus oncogene silences innate immune response Human papillomavirus type 16, the most frequent cause of cervical cancer, is able to silence a signalling molecule in the host cells that is needed for immune responses to occur. If the body is unable to defend itself against intruders, the viruses can successfully invade the cells of the cervical mucosa. Researchers from the German Cancer Research Centre have discovered that the viral E6 oncogene is responsible for this mechanism.https://www.gesundheitsindustrie-bw.de/en/article/press-release/papillomavirus-oncogene-silences-innate-immune-response
Article - 15/10/2012 Vegetables help fend off bacteria in the intestines Their discovery in the human intestines came as quite a surprise up until a few years ago LTi lymphoid tissue inducer - cells were only known to be involved in the embryonic development of the immune system. A team of researchers led by Prof. Dr. Andreas Diefenbach from the University of Freiburg Medical Centre has since been able to show the protective role played by LTi cells in fortifying the intestinal wall as a reaction to nutrients found…https://www.gesundheitsindustrie-bw.de/en/article/news/vegetables-help-fend-off-bacteria-in-the-intestines
Article - 18/03/2010 Cancer treatment adapted to individual patient requirements There is still no treatment available for a number of non-Hodgkin B-cell lymphomas. Chemotherapy, which is the standard method of treating the lymphomas, has unpleasant side effects. Researchers led by Prof. Dr. Hendrik Veelken at the Freiburg University Medical Centre in cooperation with Freiburg-based CellGenix Technologie Transfer GmbH have developed a promising new treatment strategy. Results of the Phase I and the Phase II study, which has…https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-treatment-adapted-to-individual-patient-requirements
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Press release - 06/06/2008 Collaborative research centre on cardiac diseases to receive further funding The German Research Foundation will continue to fund the Transregional Collaborative Research Centre Inflammatory Cardiomyopathy - Molecular Pathogenesis and Therapy for another four years with a total of 10 million euros. The Department of Cardiology of the University Hospital of Tübingen will also become part of the SFB.https://www.gesundheitsindustrie-bw.de/en/article/press-release/collaborative-research-centre-on-cardiac-diseases-to-receive-further-funding
Article - 27/01/2014 immatics biotechnologies GmbH: active against cancer immatics biotechnologies GmbH is a biopharmaceutical company wholly concerned with the development of advanced immunotherapies that are active against different types of cancer, including renal cell, colorectal, brain and gastric cancer. The company currently has a workforce of 80 at its headquarters in Tübingen and subsidiary in Munich. It capitalises on the know-how in the analysis of tumour cells and vaccine development gained through its…https://www.gesundheitsindustrie-bw.de/en/article/news/immatics-biotechnologies-gmbh-active-against-cancer
Article - 23/02/2015 Systems biology: Ulm scientists' search for molecules that delay ageing As stem cells get older, they gradually lose their ability to grow and reproduce. They accumulate damage and lose their ability to regenerate, thus knocking tissue homeostasis off balance. If stem cell ageing could be delayed or, even better, reversed, organs would work longer more effectively. The SyStaR research consortium is using systems biology methods and tools to investigate the mechanisms of age-dependent reduction of stem cell function…https://www.gesundheitsindustrie-bw.de/en/article/news/systems-biology-ulm-scientists-search-for-molecules-that-delay-ageing
Article - 20/10/2014 QIAGEN Lake Constance – pocket-sized laboratories for the efficient identification of pathogens Quick, simple and decentralized – this is how QIAGEN Lake Constance GmbH envisages diagnostics applications in the future. The Stockach-based QIAGEN subsidiary develops test systems for point-of-need diagnostics, i.e. tests that can be carried out in close proximity to the sample collection point, for example in GP surgeries. They enable the rapid identification of pathogens, and as a result the timely initiation of suitable treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/qiagen-lake-constance-pocket-sized-laboratories-for-the-efficient-identification-of-pathogens
Article - 13/05/2008 Just follow your nose Sharks can sense a few drops of blood in water. In fact they are able to smell blood in dilutions of as little as one to 10 billion. Is it just sharks or piranhas that have such an acute sense of smell? The answer is no - all fish have a highly developed sense of smell.https://www.gesundheitsindustrie-bw.de/en/article/news/just-follow-your-nose
Article - 30/04/2010 Silke Hofmann: Why does our body sometimes fight its own skin? The skin is the largest organ in the human body. It is not known why the immune system sometimes forms autoantibodies against it. This process can lead to blistering diseases such as pemphigus or bullous pemphigoid. Dr. Silke Hofmann from the Department of Dermatology at the University of Freiburg is investigating the molecular mechanisms that lead to such diseases. As she finds dermatology a very fascinating subject she does not restrict herself…https://www.gesundheitsindustrie-bw.de/en/article/news/silke-hofmann-why-does-our-body-sometimes-fight-its-own-skin
Press release - 30/06/2009 Gentle rather than radical: ways to improve the treatment of autoimmune diseases Autoimmune diseases are usually treated with drugs that block the entire immune system rendering the body very susceptible to all kinds of infections. A team of Constance researchers under the leadership of Prof. Marcus Groettrup has developed a treatment method that only targets part of the immune system and is therefore far better tolerated by patients. https://www.gesundheitsindustrie-bw.de/en/article/press-release/gentle-rather-than-radical-ways-to-improve-the-treatment-of-autoimmune-diseases
Article - 15/03/2010 Cystic fibrosis therapy is making good progress Thirty years ago cystic fibrosis CF formerly also known as mucoviscidosis was considered to be a disease that only affected children. Hardly any children with this hereditary metabolic disease ever reached early adulthood. Since then both the therapy and the life expectancy of CF patients have improved considerably. Dr. Gerd Döring from Tübingen is investigating the occurrence of respiratory tract defects that are common in CF patients.https://www.gesundheitsindustrie-bw.de/en/article/news/cystic-fibrosis-therapy-is-making-good-progress
Press release - 17/09/2010 Receptor blockage improves lung function in cystic fibrosis Dr. Dominik Hartl, who was recently appointed professor at the University Children’s Hospital in Tübingen, particularly focuses on the cellular processes associated with airway inflammation in cystic fibrosis. His research results will be featured as the cover story in Nature Medicine in September 2010.https://www.gesundheitsindustrie-bw.de/en/article/press-release/receptor-blockage-improves-lung-function-in-cystic-fibrosis
Article - 23/08/2010 Antibiotics for the prevention of malaria Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
Article - 24/05/2008 Funding of two million Swiss Francs The Thurgau Biotechnology Institute BITg located in Kreuzlingen and associated with the University of Constance will receive a total of 1.98 million Swiss Francs over the next four years. Between 2004 and 2008 the BITg already received about 400000 Swiss Francs per year.https://www.gesundheitsindustrie-bw.de/en/article/press-release/funding-of-two-million-swiss-francs
Article - 10/02/2008 The only professorship for preclinical imaging in Europe is in Tübingen The University of Tübingen opened its new laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens Foundation. The professorship is the only one in Europe combining preclinical imaging and the development of new imaging technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/the-only-professorship-for-preclinical-imaging-in-europe-is-in-tuebingen
Article - 26/09/2008 University Hospital of Ulm combines forces The Comprehensive Infectious Diseases Centre at the University of Ulm was recently presented to the public. The centre is responsible for coordinating the cooperation between specialists in the diagnosis and therapy of complex infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/news/university-hospital-of-ulm-combines-forces
Guest article - 21/07/2014 China - experiencing something new every single day The Baden-Württemberg Ministry of Science, Research and the Arts finances a scholarship scheme called “Research stay for application-oriented bioscientists and biotechnologists in Shanghai and Jiangsu/China”. A recent winner of this scholarship, Felix Wertek, spent six months at the Chinese Academy of Science in Shanghai and collected first-hand impressions of Chinese laboratory practice. Here, Felix reports about his exciting time in the Chinese…https://www.gesundheitsindustrie-bw.de/en/article/news/china-experiencing-something-new-every-single-day
Press release - 23/08/2010 Dr. Carsten Daub – team leader at the Bioinformatics Core Facility of RIKEN in Yokohama Dr. Carsten Daub a German bioinformatician who first studied chemistry at the TU Berlin did his doctoral degree in 2004 at the MPI of Molecular Plant Physiology in Potsdam Germany and after a two years post-doctoral training at the Karolinska Institutets Center or Genomics and Bioinformation in Stockholm Sweden joined the Genome Sciences Center at RIKEN in April 2006 on a five years contract.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dr-carsten-daub-team-leader-at-the-bioinformatics-core-facility-of-riken-in-yokohama
Article - 09/02/2015 Joining forces to develop anti-cancer immunotherapies No cancer therapy is currently achieving such promising results as immunotherapy. The German Cancer Research Center and Bayer HealthCare have established a joint laboratory to develop novel immunotherapies that selectively reactivate the body’s own immune system and incite it to attack tumour cells, thereby supporting the faster translation of concepts from the laboratory into clinical application.https://www.gesundheitsindustrie-bw.de/en/article/news/joining-forces-to-develop-anti-cancer-immunotherapies
Article - 15/03/2010 Campaign to eradicate malaria After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria